Actively Recruiting

Age: 2Years - 17Years
All Genders
NCT06756022

Dolasetron for the Prevention of CINV in Children With Acute Lymphoblastic Leukemia

Led by Anhui Provincial Children's Hospital · Updated on 2025-01-01

500

Participants Needed

1

Research Sites

57 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This is a prospective, multicenter, real-world study of 500 participants with childhood acute lymphoblastic leukemia who are scheduled to receive dolasetron mesylate injection for prophylaxis against chemotherapy-induced nausea and vomiting. This study did not make any decision or process intervention for clinical antitumor therapy. The study plans to observe the control of nausea and vomiting within 120 h (D1-D5) after receiving induction chemotherapy and the safety within 7 days (or until this discharge, whichever occurs first). During the whole study, demographic data, history of motion sickness, ECOG score, complications, name and dosage of anti-tumor therapy drugs, this antiemetic regimen, nausea and vomiting, rescue therapy drugs, combined drugs and adverse events were recorded.

CONDITIONS

Official Title

Dolasetron for the Prevention of CINV in Children With Acute Lymphoblastic Leukemia

Who Can Participate

Age: 2Years - 17Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age 2 to 17 years old
  • Diagnosed with acute lymphoblastic leukemia confirmed by bone marrow cell morphology, immune typing, cytogenetics, and molecular biology
  • Planned to receive first induction remission therapy such as VDLP/VDLD+CAM, CCCG ALL 2015 protocol, SCCCG-ALL-2023 protocol, or similar
  • Eastern Cooperative Oncology Group (ECOG) performance status score 0-2
  • Expected survival longer than 3 months
  • Subject or guardian able to read, understand, and complete the subject diary
Not Eligible

You will not qualify if you...

  • Allergy to dolasetron mesylate injection or its excipients
  • Prolonged QTc interval (QT interval 60460 ms)
  • Any other conditions the researchers consider unsuitable for participation

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Anhui Children's Hospital

Hefei, Anhui, China

Actively Recruiting

Loading map...

Research Team

T

Tianping Chen

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here